柔红霉素治疗小儿白血病心脏毒性临床分析  

The clinical analysis of daunorubicin-induced cardiotoxicity in the treatment of childhood leukemia.

作　　者：李萍[1] 胡潇滨[1] 胡宛如[1] 张乾忠[1] 

机构地区：[1]中国医科大学附属第一医院儿科,辽宁沈阳110001

出　　处：《中国实用儿科杂志》2008年第8期602-604,共3页Chinese Journal of Practical Pediatrics

摘　　要：目的探讨柔红霉素在治疗小儿急性白血病中产生的心脏毒性。方法总结1990年1月至2007年5月在中国医科大学附属第一医院就诊的92例接受柔红霉素治疗的急性白血病患儿临床资料,对其中12例发生心脏毒性的患儿按药物累积量进行分组分析。结果92例患儿中有12例出现心脏毒性,年龄越小,累积量越大,心脏毒性发生率越高。结论治疗白血病患儿时应严格控制柔红霉素累积剂量,定期对心脏进行相关检查,长期随访以便及早发现心脏损伤。Objective To investigate the daunorubicin-induced （ DNR） cardiotoxicity in the treatment of pediatric acute leukemia. Methods We Collected 92 cases of pediatric acute leukemia that were treated with DNR, choosing the children with cardiotoxicity, dividing them into groups and analyzing according to clinical types and accumulated doses. Results Twelve of the 92 cases showed eardiotoxicity, in which chronic secondary eardiotoxieity were common. If the child was younger,the accumulated dose was larger, and the incidence of eardiotoxieity was higher. Conclusion For the children treated with DNR, accumulated doses should be reasonably controlled, and drug toxicity monitoring should be done regularly. Long-term follow-up is needed so that heart injury can be detected promptly.

关 键 词：柔红霉素 白血病 心脏毒性 

分 类 号：R72[医药卫生—儿科]